Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced that its President and CEO, Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific rationale for treating Alzheimer's disease as a multi-protein disorder, emphasizing Annovis's approach of simultaneously targeting multiple neurotoxic proteins with its lead drug candidate, buntanetap.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of several neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The drug is currently in a pivotal Phase 3 clinical trial.
The presentation at Fierce Biotech Week underscores the growing interest in multi-target approaches for Alzheimer's, a disease characterized by complex pathology involving multiple protein aggregates. Most current therapies focus on single targets, such as amyloid beta, but Annovis's strategy seeks to tackle the broader protein dysfunction believed to drive neurodegeneration. If successful, buntanetap could offer a more comprehensive treatment option for patients with Alzheimer's and Parkinson's diseases.
Annovis is headquartered in Malvern, Pennsylvania, and its mission is to develop treatments that address the root causes of neurodegeneration. The company's research highlights the interconnectedness of neurotoxic proteins in disease progression, and its approach has the potential to change the treatment landscape for millions of patients worldwide. For more information about Annovis, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
The full press release is available at https://ibn.fm/kZ2Z4. Investors can find the latest news and updates relating to ANVS in the company's newsroom at https://ibn.fm/ANVS.